BRNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Barinthus Biotherapeutics PLC (BRNS) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available. The stock shows a bearish technical trend, weak financial performance, and lacks positive catalysts or strong trading signals. The absence of recent news or significant insider/hedge fund activity further diminishes its appeal.
The stock is in a bearish trend with MACD below 0 and negatively expanding, RSI at 21.796 in the neutral zone, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The price is below the pivot level of 0.672, with key support at 0.599 and resistance at 0.744.
H.C. Wainwright raised the price target to $4 and maintained a Buy rating, which could indicate long-term potential.
The company's Q3 financials show a 100% drop in revenue, negative gross margin, and a significant net income loss despite some YoY improvement. No recent news, insider trading, or hedge fund activity suggests a lack of immediate positive momentum.
In Q3 2025, revenue dropped to 0 (-100% YoY), net income increased to -$14.57M (up 79.52% YoY), and EPS improved to -0.36 (up 71.43% YoY). Gross margin dropped to 0 (-100% YoY), indicating poor operational performance.
H.C. Wainwright raised the price target from $3 to $4 and maintained a Buy rating, reflecting optimism despite weak financials.
